Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

AVEO Pharmaceuticals Inc

+ Add to Watchlist

AVEO:US

0.9465 USD 0.0345 3.78%

As of 20:10:00 ET on 01/30/2015.

Snapshot for AVEO Pharmaceuticals Inc (AVEO)

Open: 0.9300 Day's Range: 0.9200 - 0.9800 Volume: 221,550
Previous Close: 0.9120 52wk Range: 0.6050 - 1.9600 1-Yr Rtn: -42.64%

Stock Chart for AVEO

No chart data available.
  • AVEO:US 0.9465
  • 1D
  • 1M
  • 1Y
0.9120
Interactive AVEO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AVEO

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.8525
Est. EPS (USD) (12/2014) -0.9600
Est. PEG Ratio -
Market Cap (M USD) 49.46
Shares Outstanding (M) 52.26
30 Day Average Volume 500,750
Price/Book (mrq) 1.4431
Price/Sale (ttm) 2.6665
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AVEO

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AVEO

Aveo Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics. The Company's lead product candidate is an oral inhibitor of the vascular endothelial growth factor, or VEGF,receptors.

Jeno GyurisChief Executive OfficerMichael P BaileyPresident & CEO:Aveo Oncology
Joseph VittiglioSenior VP/General Counsel
More Company Profile & Key Executives for AVEO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil